Partha Narayan Dey

Dr. Partha Narayan Dey

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Cell Calcium
Verified
Journal Article
Closed access
PMPamela Maher
Pamela Maher
KLKlaus van Leyen
Klaus van Leyen
PDPartha Narayan Dey
Partha Narayan Dey
BHBirgit Honrath
Birgit Honrath
ADAmalia Dolga
Amalia Dolga
AMAxel Methner
Axel Methner

1 November 2013 in Neuron
Verified
Journal Article
Closed access
TYTifei Yuan
Tifei Yuan
MMManuel Mameli
Manuel Mameli
EOEoin C. O'COnnor
Eoin C. O'COnnor
PDPartha Narayan Dey
Partha Narayan Dey
CVChiara Verpelli
Chiara Verpelli
CBCamilla Bellone
Camilla Bellone

4 September 2018 in eLife
Verified
Journal Article
Open access
IAIsabelle Arnoux
Isabelle Arnoux
MWMichael Willam
Michael Willam
NGNadine Griesche
Nadine Griesche
JKJennifer Krummeich
Jennifer Krummeich
HWHirofumi Watari
Hirofumi Watari
ASAlbrecht Stroh
Albrecht Stroh
Catching primal functional changes in early, ‘very far from disease onset’ (VFDO) stages of Huntington’s disease is likely to be the key to a successful therapy. Focusing on VFDO stages, we assessed neuronal microcircuits in premanifest Hdh150 knock-in mice. Employing in vivo two-photon Ca2+ imaging, we revealed an early pattern of circuit dysregulation in the visual cortex - one of the first regions affected in premanifest Huntington’s disease - characterized by an increase in activity, an enhanced synchronicity and hyperactive neurons. These findings are accompanied by aberrations in animal behavior. We furthermore show that the antidiabetic drug metformin diminishes aberrant Huntingtin protein load and fully restores both early network activity patterns and behavioral aberrations. This network-centered approach reveals a critical window of vulnerability far before clinical manifestation and establishes metformin as a promising candidate for a chronic therapy starting early in premanifest Huntington’s disease pathogenesis long before the onset of clinical symptoms.

3 January 2012 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SGSWETHA k GODAVARTHI
SWETHA k GODAVARTHI
PDPartha Narayan Dey
Partha Narayan Dey
MMMegha Maheshwari
Megha Maheshwari
NJNikhil Ranjan Jana
Nikhil Ranjan Jana
Angelman syndrome (AS) is a neurodevelopmental disorder caused due to deletions or loss-of-function mutations in maternally inherited UBE3A. Ube3a functions as an ubiquitin ligase as well as a transcriptional coactivator of steroid hormone receptors. However, the mechanisms by which maternal Ube3a deficiency gives rise to phenotypic features of AS are not clear. We report here that Ube3a regulates glucocorticoid receptor (GR) transactivation and GR signaling pathway is disrupted in Ube3a-maternal-deficient mice brain. The expression of several GR-dependent genes is down-regulated in multiple brain regions of Ube3a-maternal-deficient mice. AS mice show significantly higher level of blood corticosterone, selective loss of GR and reduced number of parvalbumin-positive inhibitory interneurons in their hippocampus that could ultimately lead to increased stress. These mice also exhibit increased anxiety-like behavior, which could be due to chronic stress. Altogether, our findings suggest that chronic stress due to altered GR signaling might lead to anxiety-like behavior in a mouse of model of AS.

21 September 2010 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SRSudheendra N.R. Rao
Sudheendra N.R. Rao
RMRanjan Maity
Ranjan Maity
JSJaiprakash Sharma
Jaiprakash Sharma
PDPartha Narayan Dey
Partha Narayan Dey
SSSusarla Krishna Shankar
Susarla Krishna Shankar
NJNikhil Ranjan Jana
Nikhil Ranjan Jana
Lafora disease (LD) is an autosomal recessive progressive myoclonic epilepsy characterized by the presence of intracellular polyglucosan inclusions commonly known as Lafora bodies in many tissues, including the brain, liver and skin. The disease is caused by mutations in either EPM2A gene, encoding the protein phosphatase, laforin, or EPM2B gene, encoding the ubiquitin ligase, malin. But how mutations in these two genes cause disease pathogenesis is poorly understood. In this study, we show that the Lafora bodies in the axillary skin and brain stain positively for the ubiquitin, the 20S proteasome and the molecular chaperones Hsp70/Hsc70. Interestingly, mutant malins that are misfolded also frequently colocalizes with Lafora bodies in the skin biopsy sample of the respective LD patient. The expression of disease-causing mutations of malin in Cos-7 cells results in the formation of the profuse cytoplasmic aggregates that colocalize with the Hsp70/Hsc70 chaperones and the 20S proteasome. The mutant malin expressing cells also exhibit proteasomal dysfunction and cell death. Overexpression of Hsp70 decreases the frequency of the mutant malin aggregation and protects from mutant malin-induced cell death. These findings suggest that Lafora bodies consist of abnormal proteins, including mutant malin, targeted by the chaperones or the proteasome for their refolding or clearance, and failure of these quality control systems could lead to LD pathogenesis. Our data also indicate that the Hsp70 chaperone could be a potential therapeutic target of LD.

9 July 2014 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
LKLaura A. Kehoe
Laura A. Kehoe
CBCamilla Bellone
Camilla Bellone
MRMathias De Roo
Mathias De Roo
AZAitor Zandueta
Aitor Zandueta
PDPartha Narayan Dey
Partha Narayan Dey
DMDominique Muller
Dominique Muller
Synaptic rearrangements during critical periods of postnatal brain development rely on the correct formation, strengthening, and elimination of synapses and associated dendritic spines to form functional networks. The correct balance of these processes is thought to be regulated by synapse-specific changes in the subunit composition of NMDA-type glutamate receptors (NMDARs). Among these, the nonconventional NMDAR subunit GluN3A has been suggested to play a role as a molecular brake in synaptic maturation. We tested here this hypothesis using confocal time-lapse imaging in rat hippocampal organotypic slices and assessed the role of GluN3A-containing NMDARs on spine dynamics. We found that overexpressing GluN3A reduced spine density over time, increased spine elimination, and decreased spine stability. The effect of GluN3A overexpression could be further enhanced by using an endocytosis-deficient GluN3A mutant and reproduced by silencing the adaptor protein PACSIN1, which prevents the endocytosis of endogenous GluN3A. Conversely, silencing of GluN3A reduced spine elimination and favored spine stability. Moreover, reexpression of GluN3A in more mature tissue reinstated an increased spine pruning and a low spine stability. Mechanistically, the decreased stability in GluN3A overexpressing neurons could be linked to a failure of plasticity-inducing protocols to selectively stabilize spines and was dependent on the ability of GluN3A to bind the postsynaptic scaffold GIT1. Together, these data provide strong evidence that GluN3A prevents the activity-dependent stabilization of synapses thereby promoting spine pruning, and suggest that GluN3A expression operates as a molecular signal for controlling the extent and timing of synapse maturation.